| Variables |
No. of Patients |
Mean survival (months) |
14 months PFS proportion (%) |
Hazard Ratio |
P value |
| Age |
≤40 years |
25 |
11.83(10.10-13.55) |
57 |
1 |
0.187 |
| >40 years |
23 |
10.22 (9.09-12.30) |
34.9 |
1.82 |
|
| Grade |
III |
31 |
12.88(11.84-13.91) |
71 |
1 |
<0.0001 |
| |
IV |
17 |
8.2 (6.06-10.36) |
0 |
6.60 |
|
| Position |
Frontal |
31 |
11.63(10.10-13.15) |
49.9 |
1 |
0.284 |
| |
Others |
17 |
10.57(8.68-12.47) |
37.4 |
1.60 |
|
| Therapy |
CT+RT |
21 |
13.85(13.56-14.13) |
71.1 |
1 |
<0.0001 |
| |
RT |
9 |
11.22 |
61.1 |
2.68 |
|
| |
No |
18 |
8 (5.94-10.06) |
0 |
7.60 |
|
| MGMT Methylation status |
|
|
|
|
| G-III Methylated |
22 |
13.62(12.89-14.35) |
83.3 |
1 |
0.026 |
| Un-methylated |
9 |
11.11(8.40- 13.82) |
44.7 |
5.40 |
|
| G-IV Methylated |
14 |
9.40(7.27-11.53) |
15.7 |
1 |
0.001 |
| Unmethylated |
3 |
2.67(1.60-3.74) |
0 |
5.96 |
|
| TP53 Methylation status |
|
|
|
|
| G-III Methylated |
10 |
13.20(11.71-14.68) |
90 |
1 |
0.274 |
| Unmethylated |
21 |
12.72(11.37-14.07) |
56.8 |
3.03 |
|
| G-IV Methylated |
4 |
4.25(0.83-7.67) |
25 |
3.54 |
0.016 |
| Unmethylated |
13 |
9.51(7.28-11.75) |
17.9 |
1 |
|
| CDKN2A Methylation status |
|
|
|
|
| G-III Methylated |
11 |
13.10(11.43-14.77) |
90 |
1 |
0.345 |
| Unmethylated |
20 |
12.75(11.43-14.07) |
60.7 |
2.65 |
|
| G-IV Methylated |
6 |
8.17(4.76-11.58) |
16.7 |
1.02 |
0.961 |
| Unmethylated |
11 |
8.18(5.48-10.88) |
35.4 |
1 |
|
|
